Francesca Pizzolo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9297516/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Case Report: Microangiopathic Hemolytic Anemia With Normal ADAMTS13 Activity. Frontiers in Medicine, 2021, 8, 589423.	2.6	Ο
2	Basophil Blood Cell Count Is Associated With Enhanced Factor II Plasma Coagulant Activity and Increased Risk of Mortality in Patients With Stable Coronary Artery Disease: Not Only Neutrophils as Prognostic Marker in Ischemic Heart Disease. Journal of the American Heart Association, 2021, 10, e018243.	3.7	17
3	Serum Uric Acid Levels, but Not rs7442295 Polymorphism of SCL2A9 Gene, Predict Mortality in Clinically Stable Coronary Artery Disease. Current Problems in Cardiology, 2021, 46, 100798.	2.4	3
4	Detection of Urinary Exosomal HSD11B2 mRNA Expression: A Useful Novel Tool for the Diagnostic Approach of Dysfunctional 11β-HSD2-Related Hypertension. Frontiers in Endocrinology, 2021, 12, 681974.	3.5	4
5	Primary aldosteronism diagnosis: is cosyntropin stimulation in adrenal venous sampling still convincing?. Journal of Hypertension, 2021, 39, 2139-2140.	0.5	0
6	Assessment of SARS-CoV-2 IgC and IgM antibody detection with a lateral flow immunoassay test. Heliyon, 2021, 7, e08192.	3.2	6
7	High Plasma Concentration of Apolipoprotein C-III Confers an Increased Risk of Cerebral Ischemic Events on Cardiovascular Patients Anticoagulated With Warfarin. Frontiers in Cardiovascular Medicine, 2021, 8, 781383.	2.4	1
8	Acute haemolysis by cold antibody during SARS-CoV-2 infection in a patient with Evans syndrome: a case report and literature review. Blood Transfusion, 2021, , .	0.4	2
9	Vitamins and epigenetics. , 2020, , 633-650.		5
10	Increased Incidence of Ischemic Cerebrovascular Events in Cardiovascular Patients With Elevated Apolipoprotein CIII. Stroke, 2020, 51, 61-68.	2.0	5
11	The Positive Association between Plasma Myristic Acid and ApoCIII Concentrations in Cardiovascular Disease Patients Is Supported by the Effects of Myristic Acid in HepG2 Cells. Journal of Nutrition, 2020, 150, 2707-2715.	2.9	11
12	A relative ADAMTS13 deficiency supports the presence of a secondary microangiopathy in COVID 19. Thrombosis Research, 2020, 193, 170-172.	1.7	57
13	Deep vein thrombosis in SARS-CoV-2 pneumonia-affected patients within standard care units: Exploring a submerged portion of the iceberg. Thrombosis Research, 2020, 194, 216-219.	1.7	15
14	The 2020 Italian Society of Arterial Hypertension (SIIA) practical guidelines for the management of primary aldosteronism. International Journal of Cardiology: Hypertension, 2020, 5, 100029.	2.2	69
15	Trace Elements Status and Metallothioneins DNA Methylation Influence Human Hepatocellular Carcinoma Survival Rate. Frontiers in Oncology, 2020, 10, 596040.	2.8	1
16	Primary Aldosteronism and Obstructive Sleep Apnea. Hypertension, 2019, 74, 1532-1540.	2.7	45
17	Urinary Metabolic Signature of Primary Aldosteronism: Gender and Subtypeâ€Specific Alterations. Proteomics - Clinical Applications, 2019, 13, e1800049.	1.6	9
18	Not Just Arterial Damage: Increased Incidence of Venous Thromboembolic Events in Cardiovascular Patients With Elevated Plasma Levels of Apolipoprotein CIII. Journal of the American Heart Association, 2019, 8, e010973.	3.7	9

FRANCESCA PIZZOLO

#	Article	IF	CITATIONS
19	Sialylated isoforms of apolipoprotein C-III and plasma lipids in subjects with coronary artery disease. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1542-1550.	2.3	10
20	A Late Diagnosis of Primary Aldosteronism. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 347-349.	2.2	5
21	Increased urinary excretion of the epithelial Na channel activator prostasin in patients with primary aldosteronism. Journal of Hypertension, 2017, 35, 355-361.	0.5	5
22	The RFC1 80G>A, among Common One-Carbon Polymorphisms, Relates to Survival Rate According to DNA Global Methylation in Primary Liver Cancers. PLoS ONE, 2016, 11, e0167534.	2.5	5
23	Clinical Management and Outcomes of Adrenal Hemorrhage Following Adrenal Vein Sampling in Primary Aldosteronism. Hypertension, 2016, 67, 146-152.	2.7	63
24	Abnormal gel flotation caused by contrast media during adrenal vein sampling. Biochemia Medica, 2016, 26, 444-450.	2.7	4
25	Circadian exosomal expression of renal thiazideâ€sensitive NaCl cotransporter (NCC) and prostasin in healthy individuals. Proteomics - Clinical Applications, 2015, 9, 623-629.	1.6	26
26	An integrated genomic-transcriptomic approach supports a role for the proto-oncogene BCL3 in atherosclerosis. Thrombosis and Haemostasis, 2015, 113, 655-663.	3.4	13
27	Apparent Mineralocorticoid Excess by a Novel Mutation and Epigenetic Modulation by <i>HSD11B2</i> Promoter Methylation. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E1234-E1241.	3.6	33
28	Hormone-Dependent Changes in Female Urinary Proteome. Advances in Experimental Medicine and Biology, 2015, 845, 103-120.	1.6	6
29	NT-proBNP, a useful tool in hypertensive patients undergoing a diagnostic evaluation for primary aldosteronism. Endocrine, 2014, 45, 479-486.	2.3	13
30	Optimizing the purification and analysis of miRNAs from urinary exosomes. Clinical Chemistry and Laboratory Medicine, 2014, 52, 345-354.	2.3	48
31	Urinary protease inhibitor Serpin B3 is higher in women and is further increased in female patients affected by aldosterone producing adenoma. Molecular BioSystems, 2014, 10, 1281.	2.9	3
32	Comment on â€~Munchausen syndrome. Journal of Hypertension, 2014, 32, 200-201.	0.5	2
33	Global DNA Hypomethylation in Peripheral Blood Mononuclear Cells as a Biomarker of Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 348-355.	2.5	59
34	Factor II Activity is Similarly Increased in Patients With Elevated Apolipoprotein CIII and in Carriers of the Factor II 20210A Allele. Journal of the American Heart Association, 2013, 2, e000440.	3.7	27
35	Urinary prostasin in normotensive individuals: correlation with the aldosterone to renin ratio and urinary sodium. Hypertension Research, 2013, 36, 528-533.	2.7	13
36	Global DNA hypomethylation in peripheral blood mononuclear cells as a biomarker of cancer risk. FASEB Journal, 2013, 27, 248.1.	0.5	0

FRANCESCA PIZZOLO

#	Article	IF	CITATIONS
37	High ferritin and low folate increases PBMCs genomic DNA methylation in association with SHMT1–1420TT variant. FASEB Journal, 2013, 27, 640.14.	0.5	0
38	Low Levels of Serum Paraoxonase Activities are Characteristic of Metabolic Syndrome and May Influence the Metabolic-Syndrome-Related Risk of Coronary Artery Disease. Experimental Diabetes Research, 2012, 2012, 1-9.	3.8	26
39	Promoter methylation in coagulation <i>F7</i> gene influences plasma FVII concentrations and relates to coronary artery disease. Journal of Medical Genetics, 2012, 49, 192-199.	3.2	57
40	Antihypertensive efficacy of spironolactone: what about sex?. Journal of Hypertension, 2011, 29, 171.	0.5	0
41	Female urinary proteomics: New insight into exogenous and physiological hormoneâ€dependent changes. Proteomics - Clinical Applications, 2011, 5, 343-353.	1.6	15
42	Folic Acid Effects on S-Adenosylmethionine, S-Adenosylhomocysteine, and DNA Methylation in Patients with Intermediate Hyperhomocysteinemia. Journal of the American College of Nutrition, 2011, 30, 11-18.	1.8	45
43	Effects of female sex hormones and contraceptive pill on the diagnostic work-up for primary aldosteronism. Journal of Hypertension, 2010, 28, 135-142.	0.5	44
44	Additive effect of LRP8/APOER2 R952Q variant to APOE Îμ2/Îμ3/Îμ4 genotype in modulating apolipoprotein E concentration and the risk of myocardial infarction: a case-control study. BMC Medical Genetics, 2009, 10, 41.	2.1	23
45	Novel serum paraoxonase activity assays are associated with coronary artery disease. Clinical Chemistry and Laboratory Medicine, 2009, 47, 432-40.	2.3	29
46	Epigenetic control of 11 beta-hydroxysteroid dehydrogenase 2 gene promoter is related to human hypertension. Atherosclerosis, 2008, 199, 323-327.	0.8	179
47	Menopause Not Aldosterone-to-Renin Ratio Predicts Blood Pressure Response to a Mineralocorticoid Receptor Antagonist in Primary Care Hypertensive Patients. American Journal of Hypertension, 2008, 21, 976-982.	2.0	11
48	Aldosterone to Renin Ratio (ARR) in Clinical use, with Reference to the Primary Care Setting: ARR to Whom, When, How, What for?. Current Hypertension Reviews, 2008, 4, 227-233.	0.9	1
49	FADS genotypes and desaturase activity estimated by the ratio of arachidonic acid to linoleic acid are associated with inflammation and coronary artery disease. American Journal of Clinical Nutrition, 2008, 88, 941-949.	4.7	286
50	Urinary cortisol to cortisone metabolites ratio in prednisone-treated and spontaneously hypertensive patients. Journal of Hypertension, 2008, 26, 486-493.	0.5	6
51	Combined Effect of Hemostatic Gene Polymorphisms and the Risk of Myocardial Infarction in Patients with Advanced Coronary Atherosclerosis. PLoS ONE, 2008, 3, e1523.	2.5	35
52	The â^'1131 T>C and S19W APOA5 gene polymorphisms are associated with high levels of triglycerides and apolipoprotein C-III, but not with coronary artery disease: an angiographic study. Atherosclerosis, 2007, 191, 409-417.	0.8	67
53	Laboratory Diagnosis of Primary Aldosteronism, and Drospirenone-Ethinylestradiol Therapy. American Journal of Hypertension, 2007, 20, 1334-1337.	2.0	23
54	ALOX5AP gene variants and risk of coronary artery disease: an angiography-based study. European Journal of Human Genetics, 2007, 15, 959-966.	2.8	37

FRANCESCA PIZZOLO

#	Article	IF	CITATIONS
55	Comparison of Confirmatory Tests for the Diagnosis of Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2618-2623.	3.6	174
56	Hyperhomocysteinemia and Mortality after Coronary Artery Bypass Grafting. PLoS ONE, 2006, 1, e83.	2.5	17
57	Plasma Aldosterone Assays: Comparison between Chemiluminescence-Based and RIA Methods. Clinical Chemistry, 2006, 52, 1431a-1432.	3.2	19
58	ALOX5AP Gene Variants and Risk of Coronary Artery Disease in Italy. An Angiography-Based Study Blood, 2006, 108, 1459-1459.	1.4	0
59	Primary hyperaldosteronism: a frequent cause of residual hypertension after successful endovascular treatment of renal artery disease. Journal of Hypertension, 2005, 23, 2041-2047.	0.5	11
60	Prevalence of Body Iron Excess in the Metabolic Syndrome. Diabetes Care, 2005, 28, 2061-2063.	8.6	181
61	Apolipoprotein C-III, n-3 Polyunsaturated Fatty Acids, and "Insulin-Resistant―Tâ^'455C APOC3 Gene Polymorphism in Heart Disease Patients: Example of Gene-Diet Interaction. Clinical Chemistry, 2005, 51, 360-367.	3.2	47
62	Urinary Prostasin. Hypertension, 2005, 46, 683-688.	2.7	55
63	Hyperhomocysteinemia in Relation to Total and Cardiovascular Death after Coronary Artery Bypass Grafting. A Prospective Study Blood, 2005, 106, 1640-1640.	1.4	Ο
64	Influence of polymorphisms in the factor VII gene promoter on activated factor VII levels and on the risk of myocardial infarction in advanced coronary atherosclerosis. Thrombosis and Haemostasis, 2004, 92, 541-549.	3.4	43
65	Low plasma vitamin B-6 concentrations and modulation of coronary artery disease risk. American Journal of Clinical Nutrition, 2004, 79, 992-998.	4.7	117
66	Aldosterone to Renin Ratio in a Primary Care Setting: The Bussolengo Study. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4221-4226.	3.6	147
67	Renovascular disease: effect of ACE gene deletion polymorphism and endovascular revascularization. Journal of Vascular Surgery, 2004, 39, 140-147.	1.1	20
68	Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease. Journal of Lipid Research, 2003, 44, 2374-2381.	4.2	111
69	ApoC-III gene polymorphisms and risk of coronary artery disease. Journal of Lipid Research, 2002, 43, 1450-1457.	4.2	61
70	Different impact of deletion polymorphism of gene on the risk of renal and coronary artery disease. Journal of Hypertension, 2002, 20, 37-43.	0.5	10
71	Cystatin C versus Creatinine in Renovascular Disease. Clinical Chemistry, 2002, 48, 2256-2259.	3.2	7
72	Homozygosity for angiotensinogen 235T variant increases the risk of myocardial infarction in patients with multi-vessel coronary artery disease. Journal of Hypertension, 2001, 19, 879-884.	0.5	28

#	Article	IF	CITATIONS
73	G20210A Prothrombin Gene Polymorphism and Prothrombin Activity in Subjects With or Without Angiographically Documented Coronary Artery Disease. Circulation, 2001, 103, 2436-2440.	1.6	44